KE­LIX ac­quires Mo­roc­can man­u­fac­tur­er; Sus­tain­abil­i­ty and char­i­ty fo­cus of Catal­en­t's cor­po­rate re­spon­si­bil­i­ty re­port

A bio­phar­ma man­u­fac­tur­er in Dubai has ac­quired PHI, a lead­ing phar­ma man­u­fac­tur­er in Mo­roc­co, as a part of a larg­er plan to pro­vide health cov­er­age for the coun­try’s res­i­dents. KE­LIX bio will use the pur­chase to ac­cel­er­ate the roll­out of that plan, which it calls As­sur­ance Mal­adie Oblig­a­toire, or AMO for short. Mo­roc­co rep­re­sents a $2 bil­lion mar­ket in an­nu­al phar­ma­ceu­ti­cal con­sump­tion.

“We be­lieve we have found in KE­LIX bio and its man­age­ment the right home for our com­pa­ny and are ex­cit­ed about what the fu­ture holds for our em­ploy­ees, our part­ners, and our busi­ness,” CEO Ali Se­drati said in a state­ment. “We have every con­fi­dence KE­LIX bio will fur­ther the reach of the com­pa­ny and con­tin­ue to per­pet­u­ate its mis­sion of pro­vid­ing qual­i­ty phar­ma­ceu­ti­cal prod­ucts to the largest pop­u­la­tion pos­si­ble.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER